Biosimilars significantly reduce health care costs in Australia, enhancing access to biologics while driving price ...

A new biosimilar for aflibercept shows similar efficacy and safety in treating neovascular age-related macular degeneration ...

A new biosimilar, SYSA1902, shows comparable efficacy and safety to ustekinumab for treating moderate-to-severe plaque ...

Number 1: The competitive landscape for bone health treatments in the US has intensified with the FDA approval of Bildyos ...

A recent Japanese study confirms that switching from originator infliximab to biosimilars maintains remission in patients who ...

New denosumab biosimilars, Bildyos and Bilprevda, enhance access to affordable osteoporosis and bone disease treatments, promising significant patient benefits.

August 2025 brought significant advancements in biosimilars, including financial successes, new product launches, and research on ongoing challenges in market access.

New denosumab biosimilars, Bildyos and Bilprevda, enhance access to affordable osteoporosis and bone disease treatments, promising significant patient benefits.

Biosimilar Misconceptions, PBM Transparency, and Value-Based Care: Insights From Canavan & O'Dell ...

While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more ...